Elisabeth Mach

Learn More
AIM To characterize vascular symptoms of Behcet's disease (BD) in patients treated for the last 10 years in the Institute of Rheumatology. MATERIAL AND METHODS Vascular symptoms of BD were studied in 151 patients with BD (mean age 33.5 +/- 9.5 years, duration of the disease 14.0 +/- 10.1 years, 104 males and 47 females, 67.4% carried HLA B51(5) antigen).(More)
OBJECTIVE Given the essential role of endothelial progenitor cells (EPCs) in endothelial repair and neovascularization, it is likely that insufficient angiogenesis seen in systemic sclerosis (SSc) is related to EPC alterations. The present study was aimed to analyze in SSc the number of circulating EPCs and their contribution into cardiovascular(More)
AIM The trial of efficacy of 6-month therapy with madecassol (tablets, ointment, powder) of patients with systemic and focal scleroderma (SS and FS). MATERIALS AND METHODS 54 patients (49 females and 5 males) aged 15 to 70 years with scleroderma running from 3 months to 15 years entered the study. 30 patients had typical SS, 24 patients had FS. Tablets(More)
AIM To evaluate clinical significance of heart rate variability (HRV) in patients with psoriatic arthritis (PsA). MATERIAL AND METHODS HRV was investigated by means of time-domain analysis of 24 h ECG ambulatory recording in 113 PsA (70 female) patients < 55-years-old and 65 age-matched healthy subjects. We assessed the presence of standard cardiovascular(More)
Antiphospholipid antibodies (aPL) represent a heterogeneous population reacting with negatively charged, less frequently neutral phospholipids and/or phospholipid-binding serum proteins. The study was made of antibodies to a wide spectrum of phospholipids: to negatively charged phospholipids such as phosphatide acid (aPA), cardiolipin (aCL),(More)
AIM To evaluate intima-media complex (IMC) thickness in patients with antiphospholipid syndrome in terms of clinical-laboratory manifestations and thrombosis risk factors. MATERIAL AND METHODS The trial included 206 patients (57 males and 149 females, age 16-59, mean age 35.9 years). Of them, 58 (28%) patients had primary antiphospholipid syndrome (PAPS)(More)
The clinical and laboratory efficacy of the combination of plasmapheresis, hemosorption disease. The combined Sjögren's disease. The combined intensive treatment led to improvement in the cases with disturbances of the peripherial and central nervous system, kidneys, blood vessels (Raynaud's syndrome), joints and muscles. The efficacy of this treatment is(More)
Twenty patients with systemic scleroderma (SSD) and Raynaud's syndrome (RS) received 30-80 mg of corinfar, a blocker of calcium channels, during 14 days. Seventeen patients responded to the treatment. The clinical effect was manifested by a decrease in the rate, duration and intensity of RS attacks. Side effects were recorded in 6 patients, but the drug was(More)